Bluejay Diagnostics Reports $2.3 Million Net Loss in Q2 2026, Focuses on Symphony Technology

Bluejay Diagnostics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $2.3 million, compared to a net loss of $2.0 million for the same period in 2025. For the six months ended June 30, 2026, the company incurred a net loss of $4.2 million, up from $3.8 million in the prior year. The increase in losses is attributed to higher research and development expenses, which rose to $1.4 million in the second quarter, primarily due to increased clinical development costs. Total operating expenses for the quarter were approximately $2.3 million, compared to $2.0 million in the same quarter of 2025.

In terms of liquidity, Bluejay reported cash and cash equivalents of $9.6 million as of June 30, 2026, a significant increase from $5.2 million at the end of 2025. This increase was largely driven by financing activities, which generated $7.7 million in cash during the first half of 2026, compared to $3.4 million in the same period of 2025. The company completed a private placement in June 2026, raising approximately $8.5 million, which included pre-funded warrants and various series of warrants. However, the company continues to face challenges, with an accumulated deficit of $45.8 million as of June 30, 2026.

Operationally, Bluejay is focused on advancing its Symphony technology platform, which aims to provide rapid diagnostic tests for critical care settings. The company has completed the development of its Symphony analyzer and is progressing towards clinical validation of its first product, the Symphony IL-6 test, which is intended for monitoring disease progression in sepsis patients. The company successfully completed patient enrollment for its SYMON-II clinical validation study in July 2026 and is now working towards analytical and clinical validation to support a regulatory submission to the FDA.

The company has also made strategic changes, including transferring the production of Symphony cartridges to a contract manufacturing facility with FDA certification. In May 2026, Bluejay entered into an agreement with Argonaut Manufacturing to provide U.S.-based manufacturing, which aims to mitigate risks associated with overseas production. Despite these advancements, Bluejay anticipates needing to raise between $10 million and $14 million in additional capital by the end of the 2027 fiscal year to support its commercialization efforts and ongoing operations.

Looking ahead, Bluejay Diagnostics aims to submit a 510(k) regulatory application to the FDA for its Symphony IL-6 test in the first half of 2027, contingent upon successful clinical trial results. The company acknowledges that its ability to continue operations is dependent on securing additional funding, and it has raised concerns about its ability to continue as a going concern if it cannot obtain the necessary capital.